Lynx1 Capital Management LP Cullinan Oncology, Inc. Transaction History
Lynx1 Capital Management LP
- $270 Million
- Q1 2025
A detailed history of Lynx1 Capital Management LP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 3,215,722 shares of CGEM stock, worth $25.2 Million. This represents 9.0% of its overall portfolio holdings.
Number of Shares
3,215,722
Previous 1,257,795
155.66%
Holding current value
$25.2 Million
Previous $15.3 Million
58.91%
% of portfolio
9.0%
Previous 5.95%
Shares
5 transactions
Others Institutions Holding CGEM
# of Institutions
155Shares Held
68.6MCall Options Held
15.6KPut Options Held
17.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$60 Million10.72% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$45.1 Million1.91% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$30.3 Million0.74% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$27.8 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$26.8 Million15.23% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $358M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...